Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

Can I Walk Again After AIDP? Recovery Chances Explained

At a Glance

Most people with AIDP eventually regain the ability to walk without help, but recovery varies. Studies report about 60% walking independently by 3 months, 80% by 6 months, and about 83% by 12 months in Europe and the Americas; progress may continue longer.

While the loss of mobility is incredibly frightening at the onset of Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) — the most common form of Guillain-Barré syndrome (GBS) — most, but not all, patients regain the ability to walk without assistance [1]. Major longitudinal studies offer strong statistical hope, showing that steady progress is common, though recovery can sometimes fluctuate or plateau.

Important Safety Note: GBS can worsen rapidly. If you experience new or worsening shortness of breath, a weak cough, trouble swallowing, choking, or fainting, notify your medical team or seek emergency care immediately. Prognostic discussions never replace acute medical monitoring.

The Timeline of Mobility Recovery

Because AIDP affects everyone differently, there is no single universal timeline, and population averages cannot predict your exact individual result. In most major studies, “independent walking” is defined as the ability to walk a short distance (such as 10 meters) unaided, without a cane, walker, or another person’s help [2][3].

  • At 3 Months: Approximately 60% of patients with GBS have regained the ability to walk independently [4].
  • At 6 Months: Roughly 80% are able to walk unaided [1].
  • At 12 Months: Robust data from the International GBS Outcome Study (IGOS) tracks recovery across different regions. Within a year, about 83% of patients in Europe and the Americas were walking unaided, while in parts of Asia, the proportion was over 90% [5].

It is crucial to understand that independent walking is a major milestone, but it does not always mean an immediate return to your prior strength, balance, or endurance [6]. Some people have persistent weakness, fatigue, or need a cane for longer distances [6]. Recovery frequently continues well past the one-year mark [7].

How Neurologists Predict Your Recovery

Early in your diagnosis, neurologists use clinical scoring systems to help forecast your recovery. Not every hospital calculates these scores, and they never replace repeated neurological examinations by your doctor.

mEGOS (modified Erasmus GBS Outcome Score):
This tool is used to estimate a population-level risk of a patient being unable to walk independently at specific time points: 4 weeks and 6 months [8]. The score relies on three main factors, usually assessed at admission and checked again around day 7 [9][8]:

  1. Age: Older age is associated with a longer expected recovery timeline [8].
  2. Preceding illness: Whether you had a gastrointestinal illness like diarrhea before the weakness began [9].
  3. Limb weakness: The severity of your weakness, usually measured by a standard strength test called the Medical Research Council (MRC) sum score [8].

Higher mEGOS scores indicate a higher risk for a longer recovery. However, this is an estimate to guide physical therapy and expectation-setting, not a personal guarantee or a fixed deadline [8].

EGRIS (Erasmus GBS Respiratory Insufficiency Score):
While you might hear EGRIS mentioned alongside mEGOS, it has a different purpose. EGRIS estimates the risk that a patient will need a ventilator for breathing support over the following week [10][11]. It does not estimate walking recovery; it helps doctors plan the safest strategy for immediate life support [11].

Factors That Influence Your Chances

Every person’s nervous system heals differently. Researchers have identified variables that influence how quickly you might regain your walking ability:

  • Initial Severity: A very strong predictor of your recovery timeline is how severe your weakness was at its absolute worst (the “nadir” of the illness) [12][13].
  • Nerve Study Results: Neurologists use electromyography (EMG) and nerve conduction studies to evaluate nerve health. Very low electrical signals (such as “CMAP amplitude”) are associated with a longer recovery [4]. However, a low reading can reflect temporary issues and does not by itself prove permanent injury; it must be interpreted alongside your physical exams [14].
  • Dysautonomia: If your autonomic nervous system (which controls automatic functions like heart rate and blood pressure) is impacted, it can correlate with poorer outcomes [12].
  • Nerve Healing Mechanisms: In AIDP, the immune system primarily attacks the myelin (the protective coating around nerves). Recovery typically involves remyelination. However, if the deeper nerve fiber itself (the axon) is injured, regrowth and reinnervation are required [4]. Axon repair is a slower process, which can lead to a longer road to walking [4][7].

Regaining mobility takes time and dedicated rehabilitation. Talk to your therapy team about safely using assistive devices like braces or walkers while your nerves heal, and celebrate the small, steady gains along the way.

Common questions in this guide

Can most people walk again after AIDP?
AIDP, the most common form of Guillain-Barré syndrome, has a generally favorable walking outlook, but recovery is not guaranteed. Studies report about 60% walking independently by 3 months, 80% by 6 months, and about 83% by 12 months in Europe and the Americas; results vary by region and individual.
How long does it usually take to walk without help after AIDP?
Recovery usually unfolds over months and can continue beyond one year. In studies, independent walking means walking about 10 meters without a cane, walker, or another person’s help; about 60% reached this milestone by 3 months and 80% by 6 months, but these averages do not set a personal deadline.
What factors affect my chance of walking again after AIDP?
Recovery can be influenced by the severity of weakness at its worst, age, a gastrointestinal illness before the weakness began, autonomic problems, and nerve-study findings. Low CMAP signals and axon injury may be linked with slower recovery, but one test result cannot determine whether nerve damage is permanent.
Can the mEGOS score predict when I will walk again?
The mEGOS score estimates population-level risk of not walking independently at about 4 weeks and 6 months using age, preceding gastrointestinal illness, and limb strength. It can help clinicians plan therapy and discuss expectations, but it cannot guarantee an individual recovery timeline.
Does the EGRIS score tell me whether I will walk again?
No. EGRIS estimates the likelihood of needing breathing support during the following week, while mEGOS is the score more directly related to walking recovery. EGRIS supports immediate respiratory planning rather than long-term mobility prediction.
Can rehabilitation help me regain walking after AIDP?
Physical therapy and rehabilitation can help you work toward safe, measurable mobility goals while your nerves heal. A brace, walker, or wheelchair may improve safety and independence temporarily, and your therapy team can match devices and exercises to your strength and progress.
What symptoms require urgent medical attention during AIDP recovery?
New or worsening shortness of breath, a weak cough, trouble swallowing, choking, or fainting requires immediate notification of the medical team or emergency care. AIDP can worsen quickly, so do not wait for a routine appointment if these symptoms appear.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Acute inflammatory demyelinating polyradiculoneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What were my mEGOS and EGRIS scores when I was admitted, and how did my mEGOS change by day 7?
  2. 2.What pattern do my nerve studies show, and how might that pattern affect my long-term prognosis?
  3. 3.Would a brace, walker, or wheelchair make me safer and more mobile while I recover?
  4. 4.What specific physical therapy milestones should we target over the next 3 to 6 months to safely restore my walking ability?
  5. 5.Are there any specific factors in my case (like dysautonomia or my age) that might slow down my mobility recovery?
  6. 6.What symptoms should prompt me to stop an exercise or immediately call the medical team?

References

References (14)
  1. 1

    Clinical characteristics of Guillain-Barré syndrome in Shenzhen: a retrospective study.

    Guo F, Yao QY, Wu XH, et al.

    BMC neurology 2025; (25(1)):72 doi:10.1186/s12883-025-04061-3.

    PMID: 39984908
  2. 2

    Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome.

    Thomma RCM, Halstead SK, de Koning LC, et al.

    Brain : a journal of neurology 2025; (148(11)):4000-4015 doi:10.1093/brain/awaf102.

    PMID: 40096525
  3. 3

    Outcome of Guillain-Barré syndrome following intravenous immunoglobulin compared to natural course.

    Kalita J, Misra UK, Chaudhary SK, et al.

    European journal of neurology 2022; (29(10)):3071-3080 doi:10.1111/ene.15500.

    PMID: 35837807
  4. 4

    Very low peroneal nerve compound muscle action potential amplitude predicts poor outcome in patients with Guillain-Barré syndrome: a prospective cohort.

    López-Hernández JC, Galnares-Olalde JA, Jorge de Saráchaga A, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(6)):3923-3928 doi:10.1007/s10072-021-05834-7.

    PMID: 35067827
  5. 5

    Regional variation of Guillain-Barré syndrome.

    Doets AY, Verboon C, van den Berg B, et al.

    Brain : a journal of neurology 2018; (141(10)):2866-2877 doi:10.1093/brain/awy232.

    PMID: 30247567
  6. 6

    Long-term outcomes of paediatric Guillain-Barré syndrome.

    Estublier B, Colineaux H, Arnaud C, et al.

    Developmental medicine and child neurology 2024; (66(2)):176-186 doi:10.1111/dmcn.15693.

    PMID: 37501281
  7. 7

    Assessment of neurological sequelae and new-onset symptoms in the long-term follow-up of paediatric Guillain-Barre syndrome: A longitudinal study from India.

    Sugumar K, Chidambaram AC, Gunasekaran D

    Journal of paediatrics and child health 2022; (58(12)):2211-2217 doi:10.1111/jpc.16185.

    PMID: 36054714
  8. 8

    Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.

    Doets AY, Lingsma HF, Walgaard C, et al.

    Neurology 2022; (98(5)):e518-e532 doi:10.1212/WNL.0000000000013139.

    PMID: 34937789
  9. 9

    [The prognosis and prognostic factor of Guillain-Barré Syndrome].

    Yamagishi Y, Kusunoki S

    Rinsho shinkeigaku = Clinical neurology 2020; (60(4)):247-252 doi:10.5692/clinicalneurol.cn-001398.

    PMID: 32238748
  10. 10

    International Validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score.

    Doets AY, Walgaard C, Lingsma HF, et al.

    Annals of neurology 2022; (91(4)):521-531 doi:10.1002/ana.26312.

    PMID: 35106830
  11. 11

    European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.

    van Doorn PA, Van den Bergh PYK, Hadden RDM, et al.

    European journal of neurology 2023; (30(12)):3646-3674 doi:10.1111/ene.16073.

    PMID: 37814552
  12. 12

    Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China.

    Zhang G, Li Q, Zhang R, et al.

    PloS one 2015; (10(7)):e0133520 doi:10.1371/journal.pone.0133520.

    PMID: 26200903
  13. 13

    Predicting respiratory failure and outcome in pediatric Guillain-Barré syndrome.

    Roodbol J, Korinthenberg R, Venema E, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2023; (44()):18-24 doi:10.1016/j.ejpn.2023.02.007.

    PMID: 36931152
  14. 14

    Dose-Effect Relationship of Motor Nerve Inexcitability on Outcome in Guillain-Barré Syndrome: A Prospective Cohort Study.

    Kumar M, Tiwari A, Kumar S, Singh R

    Annals of Indian Academy of Neurology 2023; (26(6)):936-942 doi:10.4103/aian.aian_641_23.

    PMID: 38229619

This page provides general information about walking recovery after AIDP and does not constitute medical advice or predict your individual outcome. Discuss your prognosis, rehabilitation plan, and any urgent symptoms with your neurologist and care team.